Withings ECG-Monitor Study

Completed · Not applicable

Conditions studied: Atrial Fibrillation

In brief

The aim of the study is to evaluate the performance of Withings WBS08 with embedded Withings ECG Monitor in the automatic detection of atrial fibrillation

Key facts

Study ID

NCT05316337

Run by

Withings

People needed

650

Starts

2022-07-15

Expected to finish

2023-09-01

Last updated by the study team

2024-03-20

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female who are 22 years of age or older,
• Subject able to read, understand, and provide written informed consent,
• Subject willing and able to participate in the study procedures as described in the consent form,
• Subject able to communicate effectively with and willing to follow instructions from the study staff.

You may not qualify if…

• Vulnerable subject with regard to regulations in force
• Subject who is deprived of liberty by judicial, medical or administrative decision,
• Underage subject,
• Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form.
• Subject within several of the above categories,
• Subject who refused to participate in the study,
• Subject mentally impaired resulting in limited ability to cooperate
• Subject with electrical stimulation by pacemaker
• Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)
• Patient unable to stay in an upright position for the duration of study measures
• Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)
• Acute pulmonary embolism or pulmonary infarction, within 90 days of screening
• Stroke or transient ischemic attack within 90 days of screening
• Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).
• History of life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)
• Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis over electrode attachment sites
• Known sensitivity to medical adhesives, isopropyl alcohol, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands
• Weight more than 180 kg

Where it is running

• FWD Clinical Research — Boca Raton, Florida, United States
• Florida Cardiovascular Research — Hialeah, Florida, United States
• Diverse Clinical Research — Miami, Florida, United States
• The Angel Medical Research — Miami Lakes, Florida, United States
• American Institute of Therapeutics — Lake Bluff, Illinois, United States
• Cambridge Medical Trials — Alexandria, Louisiana, United States
• Heartbeat Health — New York, New York, United States
• Texas Heart Institute — Houston, Texas, United States
• LINQ Research LLC — Pearland, Texas, United States
• Henri-Mondor Hospital — Créteil, Île-de-France Region, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.